Rezolute Inc. Company Profile
NASDAQ: RZLTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rezolute at a glance
Rezolute Inc. (NASDAQ: RZLT) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Redwood City, CA. Rezolute is led by Mr. Nevan Charles Elam J.D. and employs about 58 people. At a market capitalization of $471.0 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001509261, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Rezolute do?
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Business description based on the company's public filings.
Company information
- Legal name
- Rezolute Inc.
- Ticker
- NASDAQ: RZLT
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Nevan Charles Elam J.D.
- Employees
- 58
- Headquarters
- 275 Shoreline Drive, Redwood City, CA, United States
- Phone
- 650 206 4507
- Website
- rezolutebio.com
- Market cap
- $471.04M
- SEC CIK
- 0001509261
Companies similar to Rezolute
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KMDAKamada Ltd. | 8.08 | +3.92% | $466.30M | vs RZLT |
| ASMBAssembly Biosciences Inc. | 23.53 | +3.11% | $479.08M | vs RZLT |
| OVIDOvid Therapeutics Inc. | 2.46 | +5.13% | $480.43M | vs RZLT |
| CAPRCapricor Therapeutics Inc. | 7.83 | -2.25% | $455.23M | vs RZLT |
| PRTAProthena Corporation plc | 8.84 | +2.67% | $453.82M | vs RZLT |
| MPLTMapLight Therapeutics Inc. | 8.83 | -3.50% | $490.73M | vs RZLT |
| DMACDiaMedica Therapeutics Inc. | 8.33 | +4.00% | $449.20M | vs RZLT |
| ARVNArvinas Inc. | 7.64 | +1.73% | $492.94M | vs RZLT |